Eisler Capital (US)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.84M Sell
9,297
-15,170
-62% -$2.83M 0.04% 329
2024
Q2
$4.2M Buy
+24,467
New +$4.05M 0.07% 228
2023
Q4
Sell
-23,295
Closed -$3.4M 269
2023
Q3
$3.47M Sell
23,295
-19,188
-45% -$2.82M 0.09% 168
2023
Q2
$5.72M Buy
42,483
+37,278
+716% +$5.47M 0.2% 98
2023
Q1
$830K Buy
+5,205
New +$796K 0.07% 174

Other funds holding ABBV

Eisler Capital (US)'s ABBV Position: Q3 2024 in Review

Eisler Capital (US) reduced its AbbVie (ABBV) stake by 62% in Q3 2024, selling an estimated $2.83M and leaving 9,297 shares worth $1.84M. The position accounts for 0.04% of the portfolio, ranked #329.

Eisler Capital (US) first reported a position in ABBV in Q1 2023 and has held it in 5 quarters since. The position peaked at $5.72M in Q2 2023. 3,500 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Eisler Capital (US) held 9,297 shares of AbbVie worth $1.84M as of Q3 2024.
  • Eisler Capital (US) sold 15,170 AbbVie shares in Q3 2024, an estimated $2.83M.
  • AbbVie made up 0.04% of Eisler Capital (US)'s portfolio in Q3 2024, its #329 holding.
  • Eisler Capital (US) first reported a position in AbbVie in Q1 2023 and has held it in 5 quarters since.
  • Eisler Capital (US)'s AbbVie position peaked at $5.72M in Q2 2023.
  • 3,500 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.